Ian Somaiya

Matthew Keeler

Raj Denhoy

Steve Lichtman

- Leap Therapeutics closed a private placement on October 8, 2025, raising **$58.88 million** in cash.  **[1509745_0001104659-25-098082_tm2528058d2_ex99-1.htm:0]** **[1509745_0001104659-25-098082_tm2528058d2_8k.htm:1]** 
- The proceeds will be used to initiate a **digital asset treasury strategy** and continue the development of therapeutic programs, including FL-501 and sirexatamab.  **[1509745_0001104659-25-098082_tm2528058d2_ex99-1.htm:0]** **[1509745_0001104659-25-098082_tm2528058d2_8k.htm:1]** 
- As part of the transaction, Leap issued **15,212,311 shares of common stock**, pre-funded warrants to purchase up to **80,768,504 shares**, and warrants to purchase an additional **71,985,605 shares** of common stock.  **[1509745_0001104659-25-098082_tm2528058d2_ex99-1.htm:0]** **[1509745_0001104659-25-098082_tm2528058d2_8k.htm:1]** 
- Winklevoss Capital, the lead investor, will provide strategic support for the digital asset strategy and has the right to nominate **two individuals to Leap's Board of Directors**, which has been increased to **12 members**.  **[1509745_0001104659-25-098082_tm2528058d2_ex99-1.htm:0]**

Leap Therapeutics Closes $58.88 Million Private Placement and Initiates Digital Asset Treasury Strategy

- **Leap Therapeutics** announced a **private placement** securing **$58,888,888 in cash commitments** led by **Winklevoss Capital** to initiate a digital asset treasury strategy.  **[1509745_0001104659-25-096966_tm2528058d1_ex99-1.htm:0]** 
- The private placement involves the issuance of **95,849,353 shares of common stock** (or pre-funded warrants) and **warrants to purchase an additional 71,887,008 shares** at an exercise price of **$0.5335 per share**, with an aggregate exercise price per Unit of **$0.61439**.  **[1509745_0001104659-25-096966_tm2528058d1_ex99-1.htm:0]** 
- A portion of the capital will also fund the continued development of Leap's therapeutic programs, **FL-501 and sirexatamab**.  **[1509745_0001104659-25-096966_tm2528058d1_ex99-1.htm:0]** 
- **Winklevoss Capital** will have the right to nominate **two individuals to Leap's Board of Directors**, including the chairperson, which will increase the board size to **12 members**.  **[1509745_0001104659-25-096966_tm2528058d1_ex99-1.htm:0]** 
- The closing of the private placement is anticipated on or about **October 8, 2025**.  **[1509745_0001104659-25-096966_tm2528058d1_ex99-1.htm:0]**

Leap Therapeutics Announces Private Placement and Digital Asset Treasury Strategy

- Leap Therapeutics secured **$58,888,888 in cash commitments** through a private investment in public equity (PIPE) offering led by **Winklevoss Capital**.  **[1509745_20251006NE90771:0]** 
- The capital will be used to initiate a **digital asset treasury strategy** and to continue the development of Leap's therapeutic programs, including FL-501 and sirexatamab.  **[1509745_20251006NE90771:0]** 
- As part of the agreement, Leap will **increase its Board of Directors to 12 members**, with Winklevoss Capital having the right to nominate two individuals, one of whom will be the chairperson.  **[1509745_20251006NE90771:0]**

- Leap Therapeutics (Nasdaq: LPTX) will present **final clinical results** from Part B of the DeFianCe study, a Phase 2 trial of its drug candidate **sirexatamab (DKN-01)**, at the European Society for Medical Oncology (ESMO) Congress 2025.  **[1509745_20250925NE82443:0]** 
- The data pertains to sirexatamab in combination with bevacizumab and chemotherapy for patients with **advanced microsatellite stable (MSS) colorectal cancer**.  **[1509745_20250925NE82443:0]** 
- The presentation is scheduled for a Mini Oral Session on **Sunday, October 19, 2025, at 4:05 p.m. CEST**.  **[1509745_20250925NE82443:0]** 
- The company also stated its plan to reduce clinical and operational activities, conserve cash, and explore strategic alternatives, including potentially **selling or partnering sirexatamab or FL-501**.  **[1509745_20250925NE82443:1]**

LEAP THERAPEUTICS (LPTX)